Patents by Inventor Michael Henry Boice

Michael Henry Boice has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TNFRSF14 / HVEM PROTEINS AND METHODS OF USE THEREOF
    Publication number: 20220185866
    Abstract: In some aspects the present invention provides methods for the treatment of B-cell lymphomas. Some such methods involve administration of HVEM ectodomain polypeptides, anti-HVEM antibodies, or anti-BTLA antibodies to subjects in need thereof. Some such methods involve use of CAR T cells, such as CD19-specific CAR T cells. The present invention also provides compositions useful in such methods. These and other embodiments of the present invention and described further herein.
    Type: Application
    Filed: February 26, 2022
    Publication date: June 16, 2022
    Inventors: Michael Henry Boice, Hans Guido Wendel, Darin Salloum
  • TNFRSF14 / HVEM proteins and methods of use thereof
    Patent number: 11261232
    Abstract: In some aspects the present invention provides methods for the treatment of B-cell lymphomas. Some such methods involve administration of HVEM ectodomain polypeptides, anti-HVEM antibodies, or anti-BTLA antibodies to subjects in need thereof. Some such methods involve use of CAR T cells, such as CD19-specific CAR T cells. The present invention also provides compositions useful in such methods. These and other embodiments of the present invention and described further herein.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: March 1, 2022
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Michael Henry Boice, Hans Guido Wendel, Darin Salloum
  • TNFRSF14 / HVEM PROTEINS AND METHODS OF USE THEREOF
    Publication number: 20200017571
    Abstract: In some aspects the present invention provides methods for the treatment of B-cell lymphomas. Some such methods involve administration of HVEM ectodomain polypeptides, anti-HVEM antibodies, or anti-BTLA antibodies to subjects in need thereof. Some such methods involve use of CAR T cells, such as CD19-specific CAR T cells. The present invention also provides compositions useful in such methods. These and other embodiments of the present invention and described further herein.
    Type: Application
    Filed: April 4, 2016
    Publication date: January 16, 2020
    Inventors: Michael Henry Boice, Hans Guido Wendel, Darin Salloum
  • TNFRSF14 / HVEM PROTEINS AND METHODS OF USE THEREOF
    Publication number: 20190071487
    Abstract: In some aspects the present invention provides methods for the treatment of B-cell lymphomas. Some such methods involve administration of HVEM ectodomain polypeptides, anti-HVEM antibodies, or anti-BTLA antibodies to subjects in need thereof. Some such methods involve use of CAR T cells, such as CD19-specific CAR T cells. The present invention also provides compositions useful in such methods. These and other embodiments of the present invention and described further herein.
    Type: Application
    Filed: April 4, 2016
    Publication date: March 7, 2019
    Inventors: Michael Henry Boice, Hans Guido Wendel, Darin Salloum